Kymera Therapeutics stock steadies as Braidwell boosts stake and Q2 revenue jumps

Published on 09/03/2026 at 19:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kymera Therapeutics stock is trading around 118.63 USD as of September 3, 2026 on Nasdaq while hedge fund Braidwell LP increases its stake and Q2 2026 revenue surges compared with the prior year, underscoring continued analyst confidence in the biotech group.

Kymera Therapeutics stock (ISIN US50153V1061) is quoted at 118.63 USD as of September 3, 2026 on the Nasdaq, valuing the clinical stage biotech group at about 9.86 billion USD according to market data summarized by MarketBeat.

Investor Braidwell increases its KYMR position

According to a September 3, 2026 filing overview from MarketBeat, hedge fund Braidwell LP lifted its stake in Kymera Therapeutics by 12 percent in the second quarter of 2026, purchasing 40,604 additional shares.

That brings Braidwell LP's holdings to 378,163 Kymera shares valued at approximately 43.4 million USD in the same filing, corresponding to about 0.45 percent of the company as of the most recent disclosure.

Q2 2026 earnings beat and strong revenue growth

In its most recent quarterly report for the period ended in the second quarter of 2026, Kymera Therapeutics reported an adjusted loss of 0.62 USD per share, beating the consensus estimate of a 0.71 USD loss per share according to the earnings summary reproduced by MarketBeat.

Revenue in the same quarter reached 65.0 million USD compared with 11.5 million USD in the prior year quarter, an increase of 465.2 percent year on year, underlining how collaboration income and milestone payments are temporarily boosting Kymera's top line in 2026.

The company nevertheless remains loss making, with a Q2 2026 net margin of negative 285.33 percent and a negative return on equity of 21.22 percent as summarized in the same data set, showing that profitability is still a medium term rather than immediate goal for the biotech.

Analyst targets and valuation context

Analysts tracked by MarketBeat currently assign Kymera Therapeutics an average rating described as Moderate Buy, with a consensus price target of 128.70 USD per share.

At the recent price level of 118.63 USD as of September 3, 2026, Kymera stock is therefore trading about 10.1 USD, or roughly 7.9 percent, below this consensus target, implying limited but still positive upside potential if analyst expectations are met.

The same overview cites a 12 month trading range between a low of 40.10 USD and a high of 130.05 USD, meaning the current price is close to 8 percent below the recent high while still almost tripling the 12 month low, a pattern that underscores how much sentiment around Kymera's pipeline has improved over the past year.

Product platform: targeted protein degradation in immunology and oncology

Kymera Therapeutics positions itself as a clinical stage biopharmaceutical company headquartered in Watertown, Massachusetts and focused on small molecule therapies that harness the body's natural protein homeostasis mechanisms, as described in its corporate profile within the same MarketBeat report.

The company relies on its proprietary Pegasus platform to design so called protein degraders intended to selectively eliminate disease causing proteins in indications across immunology and oncology, an approach that aims to open up targets considered difficult to address with conventional inhibitors and that helps explain the strong revenue jump from Q2 2025 to Q2 2026 as collaboration projects progress.

Kymera Therapeutics stock on Nasdaq

With Kymera Therapeutics stock trading at 118.63 USD as of September 3, 2026 on Nasdaq and a reported market capitalization of 9.86 billion USD in the MarketBeat data set, the valuation already discounts significant future growth, but the sharp 465.2 percent year on year revenue increase in Q2 2026 and a share price that remains below both the 130.05 USD 12 month high and the 128.70 USD analyst consensus target mean that the stock continues to reflect both pipeline opportunity and execution risk.